Supar Predicts Cardiovascular Outcomes In Heart Failure Independently Of High Sensitivity Troponin I

Introduction: Soluble urokinase-type plasminogen activator receptor (suPAR) is a novel biomarker that reflects immune activation, and predicts adverse outcomes including incident heart failure (HF) in the general population. Hypothesis: We hypothesized that suPAR levels will be elevated in HF, and associated with adverse outcomes including incident HF, independent of myocardial-specific biomarkers such as high-sensitivity troponin I (hs-TnI). Methods: We measured plasma suPAR and hs-TnI levels in 5001 patients undergoing cardiac catheterization and enrolled in the Emory Cardiovascular Biobank. Patients were followed for a median of 5 years for adverse events including death, myocardial infarction, hospitalization for HF, and incident HF. Survival analyses using Cox regression were performed after adjusting for clinical characteristics including coronary artery disease severity, medications and hs-TnI levels. Results: We identified 1501 patients with HF (mean age 64±13, 66% male, 26% African American, 31% ...